Cargando…

Efficacy of infectious bronchitis virus vaccines against heterologous challenge

Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis vi...

Descripción completa

Detalles Bibliográficos
Autores principales: MUNEER, M.A., NEWMAN, J.A., HALVORSON, D.A., SIVANANDAN, V., NAGARAJA, K.V., COON, C.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131188/
https://www.ncbi.nlm.nih.gov/pubmed/2851866
http://dx.doi.org/10.1016/S0034-5288(18)30889-0
_version_ 1783517181679501312
author MUNEER, M.A.
NEWMAN, J.A.
HALVORSON, D.A.
SIVANANDAN, V.
NAGARAJA, K.V.
COON, C.N.
author_facet MUNEER, M.A.
NEWMAN, J.A.
HALVORSON, D.A.
SIVANANDAN, V.
NAGARAJA, K.V.
COON, C.N.
author_sort MUNEER, M.A.
collection PubMed
description Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis virus (aibv) to determine the effects of heterologous virus exposure on egg production, egg quality and serum antibody response of the birds. The challenged hens laid significantly (P<0·005) fewer eggs than the unchallenged layers. Eggs laid by the unchallenged groups weighed significantly more (P<0·005) than those laid by the challenged groups. Further, the internal quality (Haugh units) and shell quality of eggs laid by the aibv-challenged hens was significantly (P<0·005) inferior to those from the unchallenged hens. In addition, the aibv-challenged hens laid more soft-shell, misshapen and small eggs than the unchallenged hens. The Arkansas serum haemagglutination inhibition (aibv-hi) titres of aibv challenged birds increased up to four weeks after challenge. The corresponding mibv haemagglutination-inhibition (mibv-hi) titres decreased during the same period. The study indicates that killed mibv vaccine offered no protection to birds exposed to heterologous aibv.
format Online
Article
Text
id pubmed-7131188
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71311882020-04-08 Efficacy of infectious bronchitis virus vaccines against heterologous challenge MUNEER, M.A. NEWMAN, J.A. HALVORSON, D.A. SIVANANDAN, V. NAGARAJA, K.V. COON, C.N. Res Vet Sci Article Twenty-four-week-old white Leghorn layers were inoculated subcutaneously with a killed Newcastle disease-infectious bronchitis (Massachusetts type) virus (mibv) vaccine. Twenty-eight weeks after vaccination, the birds were challenged intraocularly with the Arkansas strain of infectious bronchitis virus (aibv) to determine the effects of heterologous virus exposure on egg production, egg quality and serum antibody response of the birds. The challenged hens laid significantly (P<0·005) fewer eggs than the unchallenged layers. Eggs laid by the unchallenged groups weighed significantly more (P<0·005) than those laid by the challenged groups. Further, the internal quality (Haugh units) and shell quality of eggs laid by the aibv-challenged hens was significantly (P<0·005) inferior to those from the unchallenged hens. In addition, the aibv-challenged hens laid more soft-shell, misshapen and small eggs than the unchallenged hens. The Arkansas serum haemagglutination inhibition (aibv-hi) titres of aibv challenged birds increased up to four weeks after challenge. The corresponding mibv haemagglutination-inhibition (mibv-hi) titres decreased during the same period. The study indicates that killed mibv vaccine offered no protection to birds exposed to heterologous aibv. Published by Elsevier Ltd. 1988-07 2018-08-23 /pmc/articles/PMC7131188/ /pubmed/2851866 http://dx.doi.org/10.1016/S0034-5288(18)30889-0 Text en Copyright © 1988 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
MUNEER, M.A.
NEWMAN, J.A.
HALVORSON, D.A.
SIVANANDAN, V.
NAGARAJA, K.V.
COON, C.N.
Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title_full Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title_fullStr Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title_full_unstemmed Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title_short Efficacy of infectious bronchitis virus vaccines against heterologous challenge
title_sort efficacy of infectious bronchitis virus vaccines against heterologous challenge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131188/
https://www.ncbi.nlm.nih.gov/pubmed/2851866
http://dx.doi.org/10.1016/S0034-5288(18)30889-0
work_keys_str_mv AT muneerma efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge
AT newmanja efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge
AT halvorsonda efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge
AT sivanandanv efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge
AT nagarajakv efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge
AT cooncn efficacyofinfectiousbronchitisvirusvaccinesagainstheterologouschallenge